Ligand Pharmaceuticals Incorporated (LGND) key performance indicators and operating metrics (8 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Adjusted Net Income (Non-GAAP) | 34.6M | FY2026-Q1 |
| Adjusted Net Income per Diluted Share | 1.63 USD_per_share | FY2026-Q1 |
| Total Royalty Revenue Forecast | 42.96M | FY2026-Q1 |
| Captisol Sales | 8.65M | FY2026-Q1 |
| Total Revenue and Other Income | 115.5M | FY2025-Q3 |
| Core Adjusted Net Income | 32M | FY2025-Q2 |
| Core Adjusted Earnings per Diluted Share | 1.60 USD_per_share | FY2025-Q2 |
| Contract Revenue and Other Income | 2.94M | FY2025-Q2 |
Back to LGND overview · LGND earnings · LGND holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.